Page 75 - GTM-1-2

Global T
Global Translational Medicineranslational Medicine Risk factors of idiopathic pulmonary fibrosis
Risk factors of idiopathic pulmonary fibrosis

https://doi.org/10.1016/j.ecoenv.2021.112030 Lancet Respir Med, 8: 807–815.
56. Lin S, Zhang R, Xu L, et al., 2020, LncRNA Hoxaas3 https://doi.org/10.1016/S2213-2600(20)30225-3
promotes lung fibroblast activation and fibrosis by targeting 63. Spagnolo P, Kropski JA, Jones MG, et al., 2021, Idiopathic
miR-450b-5p to regulate runx1. Cell Death Dis, 11: 706.
pulmonary fibrosis: Disease mechanisms and drug
https://doi.org/10.1038/s41419-020-02889-w development. Pharmacol Ther, 222: 107798.
57. Li X, Yu T, Shan H, et al., 2018, LncRNA PFAL promotes https://doi.org/10.1016/j.pharmthera.2020.107798
lung fibrosis through CTGF by competitively binding miR- 64. Glass DS, Grossfeld D, Renna HA, et al., 2022, Idiopathic
18a. FASEB J, 32: 5285–5297.
pulmonary fibrosis: Current and future treatment. Clin
https://doi.org/10.1096/fj.201800055R Respir J, 16: 84–96.
58. Savary G, Dewaeles E, Diazzi S, et al., 2019, The long https://doi.org/10.1111/crj.13466
noncoding RNA DNM3OS Is a reservoir of fibromirs
with major functions in lung fibroblast response to TGF-β 65. Somogyi V, Chaudhuri N, Torrisi SE, et al., 2019, The
therapy of idiopathic pulmonary fibrosis: What is next? Eur
and pulmonary fibrosis. Am J Respir Crit Care Med, 200:
184–198. Respir Rev, 28: 190021.
https://doi.org/10.1183/16000617.0021-2019
https://doi.org/10.1164/rccm.201807-1237OC
66. Hirani N, MacKinnon AC, Nicol L, et al., 2021, Target
59. Yang Y, Tai W, Lu N, et al., 2020, LncRNA ZFAS1 promotes
lung fibroblast-to-myofibroblast transition and ferroptosis inhibition of galectin-3 by inhaled TD139 in patients with
via functioning as a ceRNA through miR-150-5p/SLC38A1 idiopathic pulmonary fibrosis. Eur Respir J, 57: 2002559.
axis. Aging (Albany, NY), 12: 9085–9102. https://doi.org/10.1183/13993003.02559-2020
https://doi.org/10.18632/aging.103176 67. Guiot J, Moermans C, Henket M, et al., 2017, Blood
biomarkers in idiopathic pulmonary fibrosis. Lung,
60. Li X, Peng C, Zhu Z, et al., 2021, The networks of m6A-
SARS-CoV-2 related genes and immune infiltration patterns 195: 273–280.
in idiopathic pulmonary fibrosis. Aging (Albany, NY), https://doi.org/10.1007/s00408-017-9993-5
13: 6273–6288.
68. Drakopanagiotakis F, Wujak L, Wygrecka M, et al., 2018,
https://doi.org/10.18632/aging.202725 Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol,
68–69: 404–421.
61. Zhang C, Wu Z, Li JW, et al., 2020, Discharge may not be the
end of treatment: Pay attention to pulmonary fibrosis caused https://doi.org/10.1016/j.matbio.2018.01.023
by severe COVID-19. J Med Virol, 93: 1378–1386.
69. Kreuter M, Lee JS, Tzouvelekis A, et al., 2021, Monocyte
https://doi.org/10.1002/jmv.26634 count as a prognostic biomarker in patients with idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med, 204: 74–81.
62. George PM, Wells AU, Jenkins RG, 2020, Pulmonary fibrosis
and COVID-19: The potential role for antifibrotic therapy. https://doi.org/10.1164/rccm.202003-0669OC

Volume 1 Issue 2 (2022) 11 https://doi.org/10.36922/gtm.v1i2.107